Trial Profile
A Randomized, Double-Blind, Within-Subject Placebo Controlled Study to Evaluate the Safety and Efficacy of Various Doses of STP705 Administered as Intradermal Injection in Subjects With Hypertrophic Scar
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 25 Nov 2021
Price :
$35
*
At a glance
- Drugs STP 705 (Primary)
- Indications Hypertrophic scars
- Focus First in man; Therapeutic Use
- Sponsors Sirnaomics
- 22 Nov 2021 Status changed from discontinued to completed.
- 20 Sep 2021 Status changed from recruiting to discontinued.
- 02 Feb 2021 According to Sirnaomics media release, the company has received IND approval from US FDA.